Analyzing the treatment type of venetoclax/venetoclax: targeted drugs or chemotherapy drugs?

Venetoclax/Venetoclax is not a chemotherapy drug in the traditional sense, but a highly selective targeted therapy drug. Unlike chemotherapy drugs, which broadly attack cancer cells, targeted drugs are specifically designed to precisely target and interfere with the specific growth and survival mechanisms of tumor cells.

Veneclar is an innovative oral small molecule inhibitor that specifically inhibitsB-cell lymphoma-2 (BCL-2) protein. Its therapeutic effect and safety have been widely verified in many blood-related diseases, especially in the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It inhibits BCL-2 protein, blocks the protein's inhibitory effect on apoptosis (cell death), and disables the self-regulation mechanism of cancer cells, thereby promoting tumor cell death. Due to its high selectivity for the BCL-2 protein and lower blood toxicity compared with similar drugs, venetoclax is regarded as a promising new star in the field of treating B cell malignancies.

Clinical practice has proven that this drug has significant effects on a variety of hematological malignant tumors with high BCL-2 protein levels. Compared with chemotherapy drugs, the advantages of targeted drugs such as venetoclax are their precision and minimal damage to normal cells. In addition, these drugs often have fewer, milder side effects and are better tolerated by patients. More importantly, targeted drugs often provide more lasting therapeutic effects and help reduce the recurrence rate of the disease.

Still, there are some possible side effects from venetoclax. Therefore, patients must strictly follow medical instructions when using it and receive regular monitoring and evaluation throughout the treatment process to ensure the safety and effectiveness of the treatment.